ArticleBMC research notes2026
Strong effect of Anti-COVID-19 vaccination on the peak titer of antibodies against novel coronavirus: factors affecting humoral immunity in Georgian plasma donors.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveHumoral responses to COVID-19 vaccination vary across populations, and evidence on the role of ABO and the Rhesus factor remains inconsistent. This prospective cohort study examined peak antibody responses among 175 voluntary plasma donors in Georgia during 2022-2023, a setting where the prevalence of Rhesus negativity is relatively high and no prior data have been reported.
resultsUsing quantitative anti-spike IgG ELISA, we measured peak antibody titers over a six-month period following vaccination and/or natural infection. Vaccination emerged as the strongest predictor of high antibody response (≥ 1000 BAU/mL), with 81.9% of vaccinated versus 21.0% of unvaccinated participants achieving protective levels (OR = 16.88, p < 0.001). Rhesus-positive individuals were significantly more likely to achieve protective titers than Rhesus-negative (57.7% vs. 30.8%, p = 0.011), while ABO blood group showed no association with antibody response (p = 0.374). Hybrid immunity provided optimal protection, with 92.5% of participants achieving elevated titers. These findings highlight vaccination and hybrid immunity as central determinants of humoral response, while identifying the Rhesus factor as an additional contributor. This study represents the first dataset of its kind from the Caucasus region, providing distinct regional evidence with implications for global immunological research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.